Controlling autoimmune diabetes onset by targeting Protease-Activated Receptor 2

CONCLUSIONS: This study highlights Par2's potential as a drug target for autoimmune diseases, particularly T1D. Our results pave the way for precision medicine approaches in treating autoimmune conditions through targeted Par2 modulation.PMID:38653114 | DOI:10.1016/j.biopha.2024.116622

Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 23, 2024 Category: Drugs & Pharmacology Authors: Gal Reches Lynn Khoon Narmeen Ghanayiem Assaf Malka Ron Piran Source Type: research